//img.uscri.be/pth/bc5e4120619d8415c550be85351d615a10383bea
Cet ouvrage fait partie de la bibliothèque YouScribe
Obtenez un accès à la bibliothèque pour le lire en ligne
En savoir plus

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health

De
9 pages
Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25–60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study. Results ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted. Conclusion ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects. Trial Registration US ClinicalTrials.gov NCT00489333
Voir plus Voir moins
Lipids in Health and Disease
BioMedCentral
Open Access Research The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health 1 11 3 Julius Oben, Ebangha Enonchong, Dieudonne Kuate, Dora Mbanya, 2 22 Tiffany C Thomas, DeWall J Hildreth, Thomas D Ingolia*and 2 Michael S Tempesta
1 Address: Laboratoryof Nutrition and Nutritional Biochemistry, Department of Biochemistry, BP 812, University of Yaoundé I, Yaoundé, 2 3 Cameroon, HealthEnhancement Products, Inc. 7740 East Evans Road, Scottsdale, AZ USA andFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon
Email: Julius Oben  juliusoben@hotmail.com; Ebangha Enonchong  juliusoben@hotmail.com; Dieudonne Kuate  juliusoben@hotmail.com; Dora Mbanya  juliusoben@hotmail.com; Tiffany C Thomas  tiffany@heponline.com; DeWall J Hildreth  dochildreth@cox.net; Thomas D Ingolia*  tingolia@heponline.com; Michael S Tempesta  natprod@aol.com * Corresponding author
Published: 5 September 2007Received: 12 June 2007 Accepted: 5 September 2007 Lipids in Health and Disease2007,6:20 doi:10.1186/1476-511X-6-20 This article is available from: http://www.lipidworld.com/content/6/1/20 © 2007 Oben et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background:Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25–60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study. Results:ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted. Conclusion:ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects. Trial Registration:US ClinicalTrials.gov NCT00489333
Page 1 of 9 (page number not for citation purposes)